Albumin-bound Paclitaxel Combined With Cisplatin Versus Docetaxel Combined With Cisplatin Induced Chemotherapy in Advanced Head and Neck Squamous Tummor
A Prospective Randomized Controlled Clinical Study of Albumin-bound Paclitaxel Combined With Cisplatin (AP Regimen) Versus Docetaxel Combined With Cisplatin (TP Regimen) Induced Chemotherapy in Advanced Head and Neck Squamous Tummor
Research Topic:
A prospective randomized controlled clinical study of albumin-bound paclitaxel combined with cisplatin (AP regimen) versus docetaxel combined with cisplatin (TP regimen) induced chemotherapy in advanced head and neck squamous cell carcinoma
Expected study duration:
Each subject received a 3-week regimen of AP or TP over 2 cycles.
Research objectives:
To evaluate the efficacy and safety of induction chemotherapy with albumin-bound paclitaxel in patients with advanced head and neck squamous cell carcinoma (HSCC), two induction chemotherapy regimens, AP regimen and TP regimen, were compared.
Trial Design. Single center, open label, controlled clinical study Number of cases: 116 Objective response rate (ORR=CR+PR) was used as the main evaluation index in this study.
研究概览
详细说明
Research purposes:Research the effectiveness and safety of albumin-bound paclitaxel for induction chemotherapy in patients with advanced head and neck squamous cell carcinoma were evaluated,by comparing the AP regimen and the TP regimen .
Research content:To evaluate the effectiveness and safety of albumin-bound paclitaxel for induction chemotherapy in patients with advanced head and neck squamous cell carcinoma.
Study endpoint Primary endpoint: Objective response rate (ORR=CR+PR) (Assessed according to RECIST standards, see Annex 1) Secondary study endpoint: Surgical resection rate,Pathological remission rate,Progression-free survival (PFS), Overall survival (OS) Main safety indicators: Observe any adverse events that occurred in all subjects during the clinical study and within 1 month after stopping the drug, including clinical symptoms, abnormal vital signs, and abnormalities in laboratory examinations, and record their clinical features, Severity, time of occurrence, duration, treatment method and prognosis outcome, and determine its correlation with the study drug. The safety of the drug was evaluated according to the NCI-CTC AE 4.0 standard.
Study design:This is a single-center, open-label, controlled clinical study.The aime is observing and evaluating the effectiveness and safety of albumin-bound paclitaxel for induction chemotherapy in patients with advanced head and neck squamous cell carcinoma.
This study is planned to be carried out in Tianjin Cancer Hospital. According to the research principles of GCP.
The study plans to recruit 116 qualified subjects. This study used objective response rate (ORR=CR+PR) as the main evaluation index. According to previous reports, the ORR of the TP group was 50%, and the ORR of the AP group was estimated to be 75%. The test level is set to 0.05 on one side, the test power is set to 0.8, and the estimated dropout rate is 20%. Using the Logrank-Lakatos algorithm, the total sample size is calculated to be 116 cases.
研究类型
注册 (预期的)
阶段
- 第四阶段
联系人和位置
学习联系方式
- 姓名:Xudong Wang, MD
研究联系人备份
- 姓名:Ze Zhang, MD
学习地点
-
-
Tianjin
-
Tianjin、Tianjin、中国、300000
- 招聘中
- Tianjin Medical University Cancer Institute And Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
Inclusion criteria:
- Age ≥18 years old, male or female;
- Subjects had squamous cell carcinoma of the head and neck confirmed by histrohistology or cytology;
- CLINICAL STAGE III OR IV WITHOUT DISTANT METASTASES (AJCC 8th)
- Patients who have not previously received initial treatment with chemotherapy or radiation;
- KPS acuity 70;
- Normal bone marrow reserve function and normal liver and kidney function;
- Expected survival time ≥3 months;
- Subjects of child-bearing age must agree to use effective contraceptive measures during the study period; The serum or urine pregnancy test must be negative for women of childbearing age 72 hours before the start of chemotherapy;
- Subjects have good compliance, can carry out treatment and follow-up, and voluntarily abide by the regulations of this study;
- Subjects voluntarily sign the informed consent.
Exclusion Criteria:
Exclusion criteria:
- Patients with distant metastasis;
- The presence of uncontrolled serious medical diseases, such as combined with serious medical diseases, including serious heart disease, cerebrovascular disease, uncontrolled diabetes, uncontrolled hypertension, uncontrolled infection, active peptic ulcer, etc.;
- The presence of dementia, altered mental status or any mental illness that would prevent understanding or giving informed consent or filling out questionnaires;
- Subjects with grade ≥2 peripheral neuropathy according to CTCAE V5.0;
- A history of allergy or hypersensitivity to any therapeutic ingredient;
- Suffered from malignant tumors other than squamous cell carcinoma of the head and neck in the past 5 years, except adequately treated basal cell or squamous cell skin cancer, local prostate cancer after radical surgery, and ductal carcinoma in situ after radical surgery;
Abnormal results of physical and laboratory tests:
A) Hematologic abnormalities are defined as:
I) Absolute count of neutrophils (ANC) : < 1.5×109 / L; Ii) Platelet (PLT) count: < 100×109/L; Iii) Hemoglobin (Hb) level < 90g/L;
B) Abnormal liver function is defined as:
I) Total bilirubin (TBIL) level: 1.5 times of the upper limit of normal value of > (ULN); Ii) AST and ALT levels of >ULN were 2.5 times, and BBB>N was 5 times if liver metastasis was present;
C) Definition of abnormal renal function:
1.5 times of serum creatinine > ULN, or the calculated creatinine clearance rate < 50ml/min;
- Patients who need to be treated with other anti-tumor drugs;
- Has received any other investigational drug therapy or participated in another interventional clinical trial within 30 days prior to screening;
- The researcher considers it unsuitable for inclusion;
- Pregnant or lactating women.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:三倍
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:albumin-bound paclitaxel combined with cisplatin (AP regimen)
Paclitaxel (albumin combined type) 260 mg/m2, intravenous drip, d1, every three weeks for a cycle, a total of dosing 2 cycles; Cisplatin: 75 mg/m2, intravenous drip, d1, every three weeks for a cycle, a total of dosing 2 cycles;
|
Paclitaxel for injection (albumin-bound) uses human serum albumin as the carrier to avoid the use of organic solvents for intravenous injection of paclitaxel, reducing the incidence of allergic reactions, and reducing the toxicity of the drug.
其他名称:
|
有源比较器:docetaxel combined with cisplatin (TP regimen)
docetaxel: 75 mg/m2, intravenous drip, d1, every three weeks for a cycle, a total of dosing 2 cycles; cisplatin: 75 mg/m2, d1 every three weeks for a cycle, a total of dosing 2 cycles;
|
Paclitaxel for injection (albumin-bound) uses human serum albumin as the carrier to avoid the use of organic solvents for intravenous injection of paclitaxel, reducing the incidence of allergic reactions, and reducing the toxicity of the drug.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Objective response rate
大体时间:21 days
|
ORR=CR+PR
|
21 days
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
操作系统
大体时间:5年
|
总生存期
|
5年
|
Surgical resection rate
大体时间:1 month
|
the rate of Surgical resection in all samples
|
1 month
|
pathological response rate
大体时间:1 month
|
the rate of pathological response in all samples
|
1 month
|
PFS
大体时间:5 year
|
progression-free survival
|
5 year
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
---|---|---|
不良事件发生率
大体时间:90天
|
不良事件发生率
|
90天
|
合作者和调查者
调查人员
- 首席研究员:Xudong Wang, MD、Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center of Cancer
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (预期的)
研究完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
albumin-bound paclitaxel的临床试验
-
Fujian Cancer HospitalJiangsu Hengrui Pharmaceutical Co., Ltd.; SunWay Biotech Co., LTD.尚未招聘肝转移 | 恶性黑色素瘤